CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
CAMBRIDGE, Mass., Oct. 27, 2015 – CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Mark Corrigan M.D., has been elected by the Board of Directors to serve as a director. Dr. Corrigan is filling a seat created by the resignation of Richard Markham, and will serve as a class II director of the Company with a term expiring at the annual meeting of stockholders to be held in 2017. In addition, Dr. Corrigan has been elected as Chairman of the Compensation Committee. CoLucid's Board remains at seven directors, six of whom are independent.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.